前列腺癌的特点是进展缓慢，即使是转移性疾病，五年生存率亦高达 30%。虽然 ADT 能有效控制疾病，但越来越多的证据显示它亦可能对患者造成许多不良心血管副作用，而由于这些患者生存期延长，这些影响尤其重要。
适应症：Cardiovascular Risk、Prostate Cancer
入组条件
纳入标准
- Adult men 18-80 years old
- With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
- Planned for ADT for at least 1 year
排除标准
- Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation
- Prior neoadjuvant or adjuvant hormone therapy within 1 year before
- Refuse or unable to give written informed consent
- Participation in an investigational program with interventions outside of routine clinical practice
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。